Salute e Benessere
New BRAVO Study Publication Reinforces Clinical Benefits of BLC in Reducing Risk of Bladder Cancer Recurrence
626 patients were included in this study, 313 in each study arm (WLC versus BLC). Outcomes data for BRAVO was measured at a 3-year time point in a predominately high-risk patient population. Median age at diagnosis was 71 years. Median follow-up was 3.7 years.
Study results include:
The Veterans' Affairs (VA) Healthcare system accepts all U.S. Veterans, regardless of financial background, and retains its patients, allowing for high-quality data capture over a long-term follow-up period, therefore serving as a robust real-world model for equal access.
said Dr. Steven Williams , Professor and Chief of the Division of Urology, at the University of Texas -Medical Branch, and one of the study authors.
said Anders Neijber, Chief Medical Officer of Photocure.
Read the full publication here: https://journals.lww.com/juop/fulltext/2025/03000/oncologic_outcomes_of_blue_light_cystoscopy_in_an.3.aspx
An editorial to the publication can be found here: https://journals.lww.com/juop/fulltext/2025/03000/editorial_comment__oncologic_outcomes_of_blue.4.aspx
*NMIBC: Non muscle-invasive bladder cancer
All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.
This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
Bladder cancer ranks as the 8 most common cancer worldwide – the 5 most common in men – with 1 949 000 prevalent cases (5-year prevalence rate) , 614 000 new cases and more than 220 000 deaths in 2022.
Approx. 75% of all bladder cancer cases occur in men. It has a high recurrence rate with up to 61% in year one and up to 78% over five years. Bladder cancer has the highest lifetime treatment costs per patient of all cancers.
Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies due to the high risk of recurrence. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall. NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.
Globocan. a) 5-year prevalence / b) incidence/mortality by population. Available at: https://gco.iarc.fr/today, accessed [ February 2024 ].
Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
Sievert KD et al. World J Urol 2009;27:295–300
Bladder Cancer. American Cancer Society. https://www.cancer.org/cancer/bladder-cancer.html
Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder, making them glow bright pink during Blue Light Cystoscopy (BLC ). BLC with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves the detection of tumors and leads to more complete resection, fewer residual tumors, and better management decisions.
Cysview is the tradename in the U.S. and Canada , Hexvix is the tradename in all other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S. and
Europe and has strategic partnerships for the commercialization of Hexvix/Cysview in
China , Chile ,
Australia , New Zealand and
Israel . Please refer to https://photocure.com/partners/our-partners for further information on our commercial partners.
The following safety information is solely included to comply with U.S. regulatory requirements:
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com/news.
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications ( Norway )
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/photocure/r/new-bravo-study-publication-reinforces-clinical-benefits-of-blc-in-reducing-risk-of-bladder-cancer-r,c4118854
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/new-bravo-study-publication-reinforces-clinical-benefits-of-blc-in-reducing-risk-of-bladder-cancer-recurrence-302401805.html